My PCR
Create Account
Logo PCR
Left main and multivessel diseaseStents, scaffolds and DCB Interventional CV surgery

EuroPCR 2026 – Long-term mortality following revascularisation for left main disease

Paris, France, 19−22 May 2026. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during EuroPCR 2026 and are set to impact practice worldwide. Among them is a meta-analysis of long-term data from 4 randomised trials investigating revascularisation strategies in patients with left main coronary artery disease. 

Background

Randomised trials have investigated the optimal revascularisation strategy for patients with left main coronary artery disease, comparing percutaneous coronary intervention (PCI) using drug-eluting stents (DES) with coronary artery bypass grafting (CABG). In 2021, a meta-analysis of 4 trials − SYNTAX, PRECOMBAT, NOBLE and EXCEL – found no statistically significant difference in 5-year all-cause mortality between DES PCI and CABG.1 Long-term follow-up of these trials is now complete, providing the opportunity to evaluate the effects of DES PCI and CABG on mortality over an extended period.

An individual participant data meta-analysis of these trials was presented by Brian Bergmark. The meta-analysis included 10-year data for SYNTAX, PRECOMBAT and NOBLE, and 5-year data for EXCEL.  

Results 

  • The meta-analysis included data from 4,394 patients.
  • Rates of all-cause mortality did not differ between patients randomised to DES PCI (23.5%) or CABG (23.1%). 
  • There were no apparent differences between the treatments amongst various subgroups studied, including baseline SYNTAX score (≤22, 23–32 and ≥33). 
  • Similar mortality results for DES PCI (22.3%) and CABG (23.3%) were obtained when analysis was restricted to trials with 10-year follow up data. 
  • In landmark analyses of all 4 trials, results were similar for DES PCI and CABG in the 0–5-year and 5–10-year follow up time periods.

Key learnings

  • There is no significant difference in mortality over 10 years of follow-up in patients with left main coronary artery disease considered suitable for revascularisation with DES PCI or CABG.  
  • These similar mortality rates were consistent across key clinical subgroups, and in both the 0–5-year and 5–10-year follow up time periods.  

Conclusions and PCR recommendations

This meta-analysis of long-term data indicates that either DES PCI or CABG may be considered for left main revascularisation in patients who are deemed to be suitable for both approaches by a multidisciplinary team. These findings strengthen the role of DES PCI in contemporary practice and endorse the role of the multidisciplinary team in clinical decision-making processes.

Reference 

  1. Sabatine MS, Bergmark BA, Murphy SA, et al. Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis. Lancet. 2021;398:2247−2257.  

NOTES TO EDITORS 

Key information

  • Session: Hotline / Late Breaking Trials: Major Late-Breaking Trials from EuroPCR 2026 
  • Presentation: Long-term mortality following PCI with DES vs. CABG for left main disease 
  • Presenter: Brian Bergmark 
  • Palais des Congrès Porte Maillot – Paris, France 
  • 20 May 2026 09:45 − 10:45 Theatre Bleu 

About EuroPCR 2026

The world-leading course in interventional cardiovascular medicine will take place from 19 to 22 May 2026, onsite at the Palais des Congrès, Paris, France. A digital package is also available for those unable to join in person.

The detailed programme is available here: www.pcronline.com/Courses/EuroPCR/Programme/2026/Course-programme

About PCR

The mission of PCR is to serve the needs of each individual patient by helping the cardiovascular community to share knowledge, experience and practice. PCR offers a large range of many other educational meetings and resources for the continuing education of the interventional cardiovascular community. These include major annual courses across the globe, e-Learning with high-profile PCR Webinars, courses specifically dedicated to valvular heart disease, tailor-made PCR Seminars on specific topics, online resources and medical publications such as EuroIntervention.

Gateways to all PCR activities are available on www.pcronline.com.
For further information, please contact Sally Collingridge: [email protected]

HELP FOR JOURNALISTS TO COVER EUROPCR 2026

Register and attend EuroPCR 2026 as a journalist

Open to accredited journalists, free of charge. Journalists must hold a valid press card and/or provide a letter of assignment from a recognised publication. To register as press, go to www.pcronline.com/Courses/EuroPCR/Press 
EuroPCR press releases can be found at www.pcronline.com/News/PCR-Press-Releases
For any press-related enquiries, please contact EuroPCR Press Coordinator, Isabelle Uzielli: [email protected]